Vivos Primêre Funksje: Eachchirurgysysteem troch Olcayto Guelec and David Geuder

Vivos Primêre Funksje: Eachchirurgysysteem troch Olcayto Guelec and David Geuder is in heech wurdearre winner fan de tige prestizjeuze 2026 A' Design Award yn Goud yn de kompetysje-kategory Medyske Apparaten en Medyske Apparatuer Ûntwerp.

GoudMedysk Produkt· 2026

Vivos Primêre Funksje: Eachchirurgysysteem

troch Olcayto Guelec and David Geuder

Klant: Geuder AG

A' Design Award yn Goud Winner yn de kategory Medysk Produkt

56,783

Ferifiearre Priiswinner

Ferifiearje Prisstatus foar #182492

Besjoch by A' Design Award Parseberjocht Priisbadge

Kleuren

It Untwerp

Oer Vivos Primêre Funksje: Eachchirurgysysteem

Boektekst: Vivos definiearret it chirurgyske wurkstasjon opnij as in platfoarm dat mei de klinyske ambysje meiûntwikkelet. Trije konfiguraasjes, Core, Nova en Nova+, wreidzje de mooglikheden út sûnder it systeem te ferfangen, de iennichste opwurdearringsarsjitektuer fan syn soarte yn eachchirurgy. Ien inkeld ynterface, falidearre op 91,7 prosint tefredenheid by earste gebrûk sûnder foarôfgeande training, wjerspegelet in ûntwerp dat om de sjirurch hinne boud is ynstee fan om de proseduere. Ferljochte ynstrumintferbiningen, ferfine materialen en beheinde detaillearring jouwe it apparaat in rêstige en selsbewuste útstrieling, frij fan it fisuele lûd dat typysk is foar de kategory.

De Erkenning

Oer de A' Design Award yn Goud

Vivos Primêre Funksje: Eachchirurgysysteem is in winner fan de A' Design Award yn Goud, in ekstreem prestisjeuze erkenning foar earste-klas, prachtige en treflike ûntwerpen. Goudwinners binne tige ynnovative, fisionêre en glamoureus ferbjusterjende skeppings dy't it sjeny, de wiisheid en de feardigens fan har ûntwerpers wjerspegelje. Fan Vivos Primêre Funksje: Eachchirurgysysteem wurdt ferwachte dat it in tige priizge, trendsettende en monumintale útfining is dy't unferlykbere wearde leveret. Dit winnende ûntwerp fan de A' Design Award yn Goud is in spektakulêr, respektearre projekt dat grutte foardielen bringt en de grinzen fan keunst, wittenskip, ûntwerp en technology ferleget. Vivos Primêre Funksje: Eachchirurgysysteem makket yntinse gefoelens fan begearte, stekt passy oan, stimulearret kreativiteit en fassinearret ús.

Efter it Untwerp

Parsepakket

Credits, teamleden en technyske details levere troch de ûntwerper.

Unike Eigenskippen: Vivos is the only ophthalmic surgery system that grows with clinical needs. Core for cataract. Nova adds vitrectomy. Plus adds laser. One platform. One interface. One training investment. Independent usability validation confirmed 92 percent user satisfaction among first time users. Illuminated connection sockets were rated positively by all study participants. Premium materials and restrained detailing give the device a likeable presence without the visual noise typical of the category.
Ofmjittingen & Ferpakking: Display: 24 inch capacitive touchscreen. Vitrectomy: up to 40000 cuts per min. Vacuum: up to 700 mmHg, highest in category. Phacoemulsification: 53 kHz piezoelectric. IOP: active real-time (VIVOS Balance). Endolaser: 532 nm. Illumination: SOLEA LED, 16.9M colours, 2 ports, Retina Protection Mode. CE pending, submitted Feb 2026. ISO 13485 2016.
Labels: Ophthalmic Surgery System, Medical Device Design, Phacoemulsification, Vitrectomy, Modular Medical Platform, Surgical Ergonomics, Workflow Design, German Medical Engineering, Usability Validation, Premium Medical Aesthetics
Produksjetechnology: Medical-grade polycarbonate housing, antimicrobial surface coating rated for over 10,000 disinfection cycles. Piezoelectric phacoemulsification at 53 kHz with beveled-up probe geometry for optimised fluidics. Pneumatic vitrectomy probe up to 40,000 cuts/min. IEC 60601-1 compliant. Modular quick-change cassette - single or multi-patient - tool-free exchange. Compatible with older phaco handpieces, protecting prior investment. Individually assembled in Heidelberg. ISO 13485:2016, IEC 62366-1, IEC 60601-1, CE pending
Untwerpútdaging: The central challenge was integrating six surgical functions, historically distributed across two to three separate devices, into a single platform without increasing cognitive load. Internally, decades of segmented product architecture and a 75-year heritage required rethinking established engineering logic. Externally, MDR regulations, IEC 62366 1 usability standards and strict OR hygiene constraints limited design freedom. Maintaining identical UX across Core, Nova and Plus while ensuring durability for thousands of cleaning cycles demanded systemic redesign rather than incremental improvement.
Undersyk: Usability research was conducted. Objective: reduce cognitive load without limiting clinical capability. Methodology: iterative co-design workshops with surgeons, Geuder teams and engineering, followed by independent summative validation per IEC 62366-1. Data collection included usability testing and task-based evaluations. Participants: 13 first-time users at RWTH Aachen University, 2026. Results: 91.7% satisfaction, no unacceptable residual risks. Insights validated the workflow UI, surgeon profiles and illuminated sockets, contributing to greater efficiency, improved patient safety and long-term system adoption in clinical practice.
Ynspiraasje: Ophthalmic surgery is precise. Why should its devices remain fragmented, complex and visually uninspiring. Anterior and posterior procedures require separate investments, training and ecosystems not because clinical need requires it but because no manufacturer redesigned the architecture around the surgeon. Geuder AG with seventy five years of ophthalmic expertise asked what if one platform could grow without hardware replacement. Validated by independent study and unique in its modular upgrade logic.
Projektdoer: The project was developed in Heidelberg, Germany by Geuder AG. Development spanned multiple months with iterative design and engineering phases conducted in close collaboration with ophthalmic surgeons and operating room nursing staff. Summative usability validation was performed at RWTH Aachen University in early 2026. CE Mark application was submitted on 27 February 2026. Public market launch is scheduled for June 2026.
Operaasjestreamferrin: Before each procedure, the surgeon selects a personal profile, preloading preferred settings and pedal sensitivity. A three-column touchscreen maps each surgical step as a visual sequence. Colour-coded modules allow instant identification in a darkened theatre. Illuminated sockets guide instrument connection by touch. The foot pedal, with individually adjustable actuation force, controls fluid flow and laser hands-free. Eye pressure is monitored and adjusted in real time.
Teamleden: Collaboration between Geuder AG's Engineering, Quality Management, Regulatory Affairs, Product Management, Service, Application, Development, and Sales departments.
Ofbyldingskrediten: Photography Geuder AG, 2026